Tags

Type your tag names separated by a space and hit enter

Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis.
J Neurol. 2020 Jun 06 [Online ahead of print]JN

Abstract

BACKGROUND

The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment.

OBJECTIVES

To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients.

MATERIALS AND METHODS

Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were "time-to-first-relapse", "time-to-Magnetic-Resonance-Imaging (MRI)-activity" and "time-to-disability-progression".

RESULTS

1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (p < 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (p < .05) at baseline. Time-varying Cox-model for the event "time-to-first relapse" revealed that no differences were found between the two groups in the first 38 months of treatment (HRt < 38DMF = 0.73, CI = 0.52 to 1.03, p = 0.079). When the time-on-therapy exceeds 38 months patients on DMF had an approximately 0.3 times lower relapse hazard risk than those who took TRF (HRt>38DMF = 3.83, CI = 1.11 to 13.23, p = 0.033). Both DMTs controlled similarly MRI activity and disability progression.

CONCLUSIONS

Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy.

Authors+Show Affiliations

Department "G.F. Ingrassia", MS Center University of Catania, Policlinico G. Rodolico, V. Santa Sofia 78, 95123, Catania, Italy. emanuele.damico@unict.it.Department "G.F. Ingrassia", MS Center University of Catania, Policlinico G. Rodolico, V. Santa Sofia 78, 95123, Catania, Italy.Department of Economics, Business and Statistics", University of Palermo, Palermo, Italy.Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy.Institute Foundation "G. Giglio", Cefalù, Italy.San Filippo Neri Hospital - ASL, Roma 1, Rome, Italy.Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.Fondazione Policlinico Universitario "Gemelli", Catholic University of Sacred Heart, Rome, Italy.Azienda Ospedaliera Universitaria "G. Martino", Messina, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.University of Campania Luigi Vanvitelli, 1st Clinic of Neurology, Naples, Italy.AOU Maggiore, Parma, Italy.Policlinico G.B. Rossi, Verona, Italy.Multiple Sclerosis Center, II Division of Neurology, Department of Clinical and Experimental Medicine, Second University of Naples, Naples, Italy.University of Campania Luigi Vanvitelli, 1st Clinic of Neurology, Naples, Italy.Policlinico G.B. Rossi, Verona, Italy.Neuroimmunology, Center for Multiple Sclerosis, ASST, Crema, Italy.University La Sapienza, Rome, Italy.Department of Advanced Medical and Surgical Sciences, University of Campania "Luigi Vanvitelli", Naples, Italy.Azienda Ospedaliera Universitaria "Mater Domini", Catanzaro, Italy.Fondazione Policlinico Universitario "Gemelli", Catholic University of Sacred Heart, Rome, Italy.AOU Maggiore, Parma, Italy.Multiple Sclerosis Clinical Care and Research Centre, Department of Neuroscience, Reproductive Science and Odontostomatology, Federico II University of Naples, Naples, Italy.Institute Foundation "G. Giglio", Cefalù, Italy.Department "G.F. Ingrassia", MS Center University of Catania, Policlinico G. Rodolico, V. Santa Sofia 78, 95123, Catania, Italy.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32506391

Citation

D'Amico, Emanuele, et al. "Dimethyl Fumarate Vs Teriflunomide: an Italian Time-to-event Data Analysis." Journal of Neurology, 2020.
D'Amico E, Zanghì A, Sciandra M, et al. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. J Neurol. 2020.
D'Amico, E., Zanghì, A., Sciandra, M., Lanzillo, R., Callari, G., Cortese, A., Lus, G., Lucchini, M., Buccafusca, M., Bonavita, S., Gallo, A., Curti, E., Gajofatto, A., Signoriello, E., Bisecco, A., Gobbin, F., Ferrò, M. T., Ferrazzano, G., Sparaco, M., ... Patti, F. (2020). Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. Journal of Neurology. https://doi.org/10.1007/s00415-020-09959-1
D'Amico E, et al. Dimethyl Fumarate Vs Teriflunomide: an Italian Time-to-event Data Analysis. J Neurol. 2020 Jun 6; PubMed PMID: 32506391.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. AU - D'Amico,Emanuele, AU - Zanghì,Aurora, AU - Sciandra,Mariangela, AU - Lanzillo,Roberta, AU - Callari,Graziella, AU - Cortese,Antonio, AU - Lus,Giacomo, AU - Lucchini,Matteo, AU - Buccafusca,Maria, AU - Bonavita,Simona, AU - Gallo,Antonio, AU - Curti,Erica, AU - Gajofatto,Alberto, AU - Signoriello,Elisabetta, AU - Bisecco,Alvino, AU - Gobbin,Francesca, AU - Ferrò,Maria Teresa, AU - Ferrazzano,Gina, AU - Sparaco,Maddalena, AU - Valentino,Paola, AU - Mirabella,Massimiliano, AU - Granella,Franco, AU - Bresciamorra,Vincenzo, AU - Grimaldi,Luigi Maria Edoardo, AU - Patti,Francesco, AU - ,, Y1 - 2020/06/06/ PY - 2020/02/20/received PY - 2020/05/28/accepted PY - 2020/05/23/revised PY - 2020/6/8/entrez KW - Dimethyl fumarate KW - Efficacy KW - Multiple sclerosis KW - Safety KW - Teriflunomide JF - Journal of neurology JO - J. Neurol. N2 - BACKGROUND: The introduction of oral disease-modifying therapies (DMTs) for relapsing-remitting multiple sclerosis (RRMS) changed algorithms of RRMS treatment. OBJECTIVES: To compare the effectiveness of treatment with dimethyl fumarate (DMF) and teriflunomide (TRF) in a large multicentre Italian cohort of RRMS patients. MATERIALS AND METHODS: Patients with RRMS who received treatment with DMF and TRF between January 1st, 2012 and December 31st, 2018 from twelve MS centers were identified. The events investigated were "time-to-first-relapse", "time-to-Magnetic-Resonance-Imaging (MRI)-activity" and "time-to-disability-progression". RESULTS: 1445 patients were enrolled (1039 on DMF, 406 on TRF) and followed for a median of 34 months. Patients on TRF were older (43.5 ± 8.6 vs 38.8 ± 9.2 years), with a predominance of men and higher level of disability (p < 0.001 for all). Patients on DMF had a higher number of relapses and radiological activity (p < .05) at baseline. Time-varying Cox-model for the event "time-to-first relapse" revealed that no differences were found between the two groups in the first 38 months of treatment (HRt < 38DMF = 0.73, CI = 0.52 to 1.03, p = 0.079). When the time-on-therapy exceeds 38 months patients on DMF had an approximately 0.3 times lower relapse hazard risk than those who took TRF (HRt>38DMF = 3.83, CI = 1.11 to 13.23, p = 0.033). Both DMTs controlled similarly MRI activity and disability progression. CONCLUSIONS: Patients on DMF had higher relapse-free survival time than TRF group after the first 38 months on therapy. SN - 1432-1459 UR - https://www.unboundmedicine.com/medline/citation/32506391/Dimethyl_fumarate_vs_Teriflunomide:_an_Italian_time-to-event_data_analysis L2 - https://dx.doi.org/10.1007/s00415-020-09959-1 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.